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Abstract
Background: The perioperative period can be a critical period with long-term implications on cancer-related
outcomes. In this study, we evaluate the influence of regional anesthesia on cancer-specific outcomes in a radical
cystectomy (RC) cohort of patients.
Methods: We performed a retrospective analysis of patients with clinically-nonmetastatic urothelial carcinoma of
the bladder who underwent RC at our institution from 2008 to 2012. Patients were retrospectively registered and
stratified based on two anesthetic techniques: perioperative epidural analgesia with general anesthesia (epidural)
versus general anesthesia alone (GA). Epidural patients received a sufentanil-based regimen (median intraoperative
sufentanil dose 50 mcg (45,85). Propensity-score was used to make 1:1 case-control matching. Cumulative risk of
recurrence with competing risks was calculated based on anesthetic technique. Kaplan-Meier curves were used to
compare recurrence-free (RFS) and cancer-specific survival (CSS). Univariable and multivariable analyses were
performed with Cox proportional hazard regression models for RFS and CSS.
Results: Only patients with complete data on anesthetic technique were included. Out of 439 patients, 215-pair
samples with complete follow-up were included in the analysis. Median follow-up was 41.4 months (range: 0.20–
101). Patients with epidurals received higher median total intravenous morphine equivalents (ivMEQ) versus those
in the GA group (75 (11–235) vs. 50 ivMEQ (7–277), p < 0.0001). Cumulative risk of recurrence at two years was
25.2% (19.6, 31.2) for epidural patients vs. 20.0% (15.0, 25.7) for GA patients (Gray test p = 0.0508). Epidural analgesic
technique was a significant predictor of worse RFS (adjusted HR = 1.67, 1.14–2.45; p = 0.009) and CSS (HR = 1.53,
1.04–2.25; p = 0.030) on multivariable analyses.
Conclusions: Epidural anesthesia using sufentanil was associated with worse recurrence and disease-free survival in
bladder cancer patients treated with surgery. This may be due use of epidural sufentanil or due to the increased
total morphine equivalents patient received as a consequence of this drug.
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Background
The perioperative period is a critical period which may
impact long-term cancer outcomes. A complex state of
inflammation, immunosuppression, angiogenesis, and
high adrenergic state has been shown to potentially
facilitate growth of residual disease and promote seeding
of circulating tumor cells [1–3]. Thus, tumor surveil-
lance and eradication are strongly dependent on an
adequate immune response to these potentially influen-
cing tumor biology [4–6].
Radical cystectomy (RC) with pelvic lymph node dis-
section is the mainstay treatment for muscle invasive
bladder cancer. A greater survival advantage has been
shown at 2 years or more following RC as opposed to
bladder-sparing modalities [7]. However, the surgical
stress response might initiate a cascade of cellular, hor-
monal, and neuronal perturbations that leave patients
susceptible to the pro-metastatic effects of tumor ma-
nipulation [4–6]. In addition, the choice of anesthetic
technique may influence cancer outcomes in two ways.
First, the immosuppressive effects of opioids, has been
proposed to possibly influence immunogenicity during
surgery in several solid organ malignancies thereby influ-
encing cancer recurrence [8, 9]. Secondly, regional
anesthesia such as epidural anesthesia may blunt the pro
metastatic effect of surgical stress [10, 11].
If one can attenuate these perioperative pro-meta-
static processes, the immediate postoperative period
could become a window of opportunity to improve
long-term oncologic control for surgical oncology pa-
tients. Given the paucity of studies in the urological
and anesthetic literature, we aim to evaluate cancer
outcomes in a matched cohort of patients undergoing
RC at our institution. Our hypothesis was that tumor
recurrence may be associated with the use of epidural
opioids.
Methods
Analgesia management and study population
The study was approved by institutional review board. We
retrospectively reviewed the medical records of all patients
who underwent RC from January 2008 and December
2012 for clinically non-metastatic urothelial carcinoma of
the bladder with curative intent. Patients were stratified
based on anesthetic technique which included a standard-
ized protocol of general endotracheal anesthesia with
epidural (epidural group) or general endotracheal
anesthesia alone (GA group). Epidural catheters were
placed at the discretion of the anesthesiologist and
surgeon. Catheters were placed between T10-T12 levels
and dosed primarily with sufentanil during the intra and
postoperative period (median intraoperative dose =
50mcg, range 45–85). Patients without epidural catheters
utilized patient-controlled analgesia with either intraven-
ous morphine or hydromorphone.
Propensity score matching based on age, American So-
ciety of Anesthesiologists (ASA) score, and pathologic N
and T stage was performed for those patients with
complete analgesic data and surveillance follow-up. In
total, 215 matched subjects from each cohort was
produced and included in the final analysis (Fig. 1). A
data driven approach was not used in selecting charac-
teristics to adjust for, rather the authors chose factors
which might cause an imbalance in comparing the two
cohorts in subsequent analysis. We agree that a
data-driven approach could have been used, but there
were no significant differences when comparing cohorts.
Additionally, propensity matching was performed using
anesthesia type as the outcome, not survival. Conse-
quently, the matching does not preclude effects of
measured and unmeasured baseline characteristics. For
this reason we also adjusted the multivariable models for
these effects.
Fig. 1 Patient Flow Diagram
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Primary outcomes
Primary outcomes measured were recurrence-free
(RFS) and cancer-specific survival (CSS). Survival was
assigned from date of surgery until date of recurrence
(RFS) or death from disease (CSS). Follow-up data
were available through our institution’s tumor registry,
which tracks patients’ death certificates and follow-up
at other medical facilities. Reasons for censoring were
lost of follow up and death from any other known
cause with documented absence of detectable disease
after regular follow up.
To investigate whether or not total perioperative use
of systemic opioids was different, we compared total
intravenous morphine equivalents (ivMEQ) given in the
intraoperative and immediate postoperative period. The
ivMEQ were calculated on the basis of 1 mg morphine
= 1mcg sufentanil, 0.2 mg hydromorphone, and 10 mcg
fentanyl [12, 13].
Statistical analysis
Frequencies, means, medians, and ranges were used in
the descriptive tables to characterize the data both in
total and by anesthesia type. For a subgroup of the vari-
ables, nonparametric tests (Wilcoxon rank sum test or
Kruskal Wallis test for continuous and Fisher’s Exact test
for categorical variables, respectively) were performed
comparing anesthesia cohorts. Cumulative risk of recur-
rence with competing risks analysis was calculated based
on anesthetic technique and compared with the Gray
test. Death was the competing event. The Kaplan-Meier
method was used to estimate RFS and CSS. Cox Propor-
tional Hazards regression was used in both univariable
and multivariable models for each endpoint. For CSS,
backwards selection process was performed. For RFS,
competing risk analysis was carried out. All analyses
were performed in either SAS (v 9.4) and R software.
This study is written in accordance to the Strengthening
Table 1 Characteristics of the sample (n = 430 patients)
Variable Level N = 430 %
Gender Male 332 77.2
Female 98 22.8
Age (years) Median 69 –
Std Dev 10.04 –
BMI (kg/m2) Median 27.85 –
Std Dev 5.27 –
Race White 404 94.0
Black 14 3.3
Asian 1 0.2
Native Hawaiian/
Pacific Islander
1 0.2
American Indian/
Alaskan
1 0.2
Unknown/Other 9 2.1
ASA score 1 3 0.7
2 194 45.1
3 224 52.1
4 9 2.1
Anesthesia groups General only 215 50.0
General + Epidural 215 50.0
Neoadjuvant
chemotherapy
No 305 71.4
Yes 122 28.6
Unknown 3 –
Diversion Type Ileal conduit 280 65.1
Continent
catherizable pouch
15 3.5
Neobladder 67 15.6
Cutaneous
ureterostomy
63 14.6
pT stage T0 59 13.7
T1 44 10.2
T2 82 19.1
T3 125 29.1
T4 62 14.4
Ta/Tis 58 13.5
pN stage Nx 19 4.4
N1 35 8.1
N2 60 14.0
N3 17 4.0
N0 299 69.5
Radial margin Negative 377 87.7
Positive 53 12.3
Ureteral or
urethral margin
Negative 402 93.5
Positive 28 6.5
Grade High 350 96.7
Table 1 Characteristics of the sample (n = 430 patients)
(Continued)
Variable Level N = 430 %
Low 5 1.4
Mixed 2 0.6
Missing 73 –
Adjuvant
chemotherapy
No 340 79.8
Yes 86 20.2
Missing 4 –
Location of
Recurrence
Pelvic 22 16.5
Upper tract 11 8.3
Distant 97 72.9
Other 3 2.3
None 297 –
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Reporting in Observational and Epidemiological studies
(STROBE) guidelines (www.strobe-statement.org).
Results
Study cohort characteristics
Demographic and tumor characteristics of the entire co-
hort are provided in Table 1. Overall, 77.2% of patients
were male. Median age was 69 years and median clinical
follow-up was 41.4 months (range: 0.20–101). Approxi-
mately 29% and 20% received neoadjuvant and adjuvant
systemic treatments, respectively. The most common
urinary diversion was the ileal conduit (65.1%). Approxi-
mately 44 and 26% had pT3/T4 and pN+ disease, re-
spectively. The positive radial and ureteral or urethral
margin rates were 12.3 and 6.5%, respectively.
The non-epidural cohort had more male patients (81.9
vs 72.6%) (p = 0.021), as well as more patients with T3/4
tumor stage (47.4 vs 39.5%) (p = 0.096). No significant
differences were found for hospital length of stay, race,
ethnicity, body mass index (BMI), median follow-up,
node stage or chemotherapy status between the two
groups (Table 2).
Patients in the epidural group had higher median total
morphine equivalents versus those in the GA group (75
(11–235) vs 50 ivMEQ (7–277), p < 0.0001) (Fig. 2).
None of the patients received intraoperative non-ster-
oidal anti-inflammatory drugs (NSAID). Postoperatively,
the NSAID use was not available.
Recurrence rates
Of the 430 patients, 133 (30.9%) developed a recurrence
with the most common type being distant metastatic
disease (72.9%). A cumulative risk for recurrence plot is
presented in Fig. 3. The median time to recurrence was
11 and 11.8 months for epidural and GA, respectively.
Majority of recurrences occurred within 2 years after RC
with rates of 20.0% (95%CI: 15.0–25.7) and 25.2% (19.6–
31.2) for GA vs. epidural patients, respectively (Gray test
p = 0.051).
Survival analysis
Figure 4 shows survival curves based on anesthesia type.
Five-year RFS and CSS for the whole cohort were 67.2%
(62.0–71.8) and 68.7% (63.3–73.5), respectively. Epidural
Table 2 Characteristics of the cohorts with tests (n = 430)
Covariate Level GA (Non-Epidural)
N = 215
Epidural
N = 215
P-value
Gender Male 176 (81.86) 156
(72.56)
0.021
Female 39 (18.14) 58
(27.44)
Age (years) Median 70 69 0.384
Follow-up
(months)
Median 40.7 42.9 0.260
Race Unknown/
Other
7 (3.26) 2 (0.93) 0.181
White 197 (91.63) 207
(96.28)
Black 8 (3.72) 6 (2.79)
Asian 1 (0.47) 0 (0)
Hawaiian/P.
Islander
1 (0.47) 0 (0)
Indian/Alaskan 1 (0.47) 0 (0)
Ethnicity Unknown/Other 138 (64.19) 140
(66.12)
0.977
Not Hispanic/
Latino
73 (33.95) 71
(33.02)
Hispanic/Latino 4 (1.86) 4 (1.86)
ASA 1 1 (0.47) 2 (0.93) 0.147
2 86 (40) 108
(50.23)
3 123 (57.21) 101
(46.98)
4 5 (2.33) 4 (1.86)
Length of
stay (days)
Median 8 7 0.352
BMI (kg/m2) Median 28.46 27.75 0.191
pT stage T0 31 (14.42) 28
(13.02)
0.096
T1 20 (9.3) 24
(11.16)
T2 30 (13.95) 52
(24.19)
T3 71 (33.02) 54
(25.12)
T4 31 (14.42) 31
(14.42)
Ta/Tis 32 (14.88) 26
(12.09)
pN stage Nx 10 (4.65) 9 (4.19) 0.808
N1 19 (8.84) 16 (7.44)
N2 33 (15.35) 27
(12.56)
N3 7 (3.26) 10 (4.65)
N0 146 (67.91) 153
Table 2 Characteristics of the cohorts with tests (n = 430)
(Continued)
Covariate Level GA (Non-Epidural)
N = 215
Epidural
N = 215
P-value
(71.16)
Neoadjuvant
chemotherapy
No 155 (72.77) 150
(70.09)
0.540
Yes 58 (27.23) 64
(29.91)
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patients had a 5-year RFS of 62.9% (55.4–69.4) vs. 70.9%
(63.5–77.2) for GA patients (log-rank p = 0.134). Five-
year CSS were 64.2% (95% CI 56.2–71.1) and 73.7%
(95% CI 66.0–79.8) (log-rank: p = 0.144) for epidural vs.
GA patients, respectively.
Predictors for RFS and CSS
Tables 3 and 4 show the results of Cox proportional
hazards modeling for RFS and CSS, respectively.
When adjusting for relevant covariates, patients who
received epidurals were at increased risk of recur-
rence (adjusted HR = 1.67, 1.14–2.45; p = 0.009) and
death of disease (HR = 1.53, 1.04–2.25; p = 0.030).
Other predictors of recurrence were age (adjusted
HR = 0.98, p = 0.045), pT stage (adjusted HR = 2.22, p
< 0.001), and neoadjuvant chemotherapy (adjusted HR
= 1.66, p = 0.009) while pN stage (HR = 2.48, p <
0.001), pT stage (HR = 3.63, p < 0.001), and margin
status (HR = 2.00, p = 0.012) were associated with
worse cancer survival.
Fig. 2 Histogram of Total Morphine Equivalents by Anesthetic technique
Fig. 3 Cumulative risk of recurrence between the two groups
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Discussion
Patients who received epidural analgesia sustained a de-
creased time to disease recurrence. Interestingly the log
rank p-values (Fig. 4) did not show a statistical differ-
ence for RFS and CSS between groups, however the uni-
variate Cox proportional hazard regression showed a
statistical difference in RFS between the epidural and
GA group. This is mostly likely due to the use of
competing risk methods that was used in the RFS ana-
lysis. Since epidural sufentanil is such a potent opioid
translating to a large ivMEQ, we believe the immuno-
suppressive effects of increased systemic opioids led to
the poor recurrence and survival outcomes seen in our
epidural cohort of patients [14].
The perioperative period is a fragile state for patients
undergoing cancer surgery and is characterized by
Fig. 4 Recurrence-free (RFS) and Cancer-specific (CSS) survival by Anesthetic technique
Table 3 Cox proportional hazards regression for recurrence-free survival (n = 430) with competing risks
Covariate Level Univariable Hazard
Ratio (95% CI)
P-value Multivariable Hazard
Ratio (95% CI)
P-value
Age 0.98 (0.96–0.99) 0.020 0.98 (0.98–1.00) 0.045
Gender Male 1.36 (0.86–2.14) 0.190 1.62 (0.99–2.66) 0.057
Female Ref
ASA ≥ 3 0.81 (0.57–1.15) 0.232 0.91 (0.62–1.33) 0.620
≤ 2 Ref
Anesthesia GA + Epidural 1.43 (1.00–2.04) 0.048 1.67 (1.14–2.45) 0.009
GA Ref
pN stage N+ 1.76 (1.21–2.55) 0.003 1.24 (0.82–1.88) 0.308
N0/Nx Ref
pT stage ≥ T3 2.47 (1.74–3.52) < 0.001 2.22 (1.43–3.46) 0.0004
≤ T2 Ref
Margin (radial/
ureteral/urethral)
Positive 1.42 (0.95–2.12) 0.091 1.23 (0.78–1.94) 0.370
Negative Ref
Neoadjuvant
chemotherapy
Yes 1.69 (1.18–2.43) 0.005 1.66 (1.14–2.43) 0.009
No Ref
Adjuvant chemotherapy Yes 2.17 (1.49–3.16) < 0.001 1.34 (0.85–2.11) 0.206
No Ref
Bold value indicates statistical significance
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various pro-metastatic processes such as release of
tumor cells, increased levels of pro-angiogenic growth
factors, and numerous hormonal and autonomic alter-
ations caused by the surgery-induced stress response
[15]. Thus, it is the synchronization of these detrimental
processes that may render a patient susceptible to poor
oncologic outcomes. Given that anesthesia and analgesia
play an integral role in perioperative recovery and pain
control, our study is significant in describing an associ-
ation between anesthetic technique and cancer out-
comes for bladder cancer patients.
Surgery induces a stress response that can affect the
host’s cytotoxic T-cell and natural killer (NK) cellular
function, increase pro-angiogenic factors that promote
tumor growth, and reduce circulating concentrations of
tumor-related anti-angiogenic factors [16–19] In addition,
systemic opioids used during hospital course can affect
both humoral and cellular immunity by inhibiting anti-
body production, NK cell activity, cytokine expression,
and phagocytic activity [14, 20–22].
One previous study of over 1000 prostatectomy
patients reported intravenous sufentanil administration
associated with increased risk of biochemical recurrence
[8]. Interestingly, 97% of patients received sufentanil
(epidural and intravenous) introducing a risk of type 1
error. Patients receiving intravenous sufentanil had a
significant reduced survival rate (HR 7.8). The authors
did not compare the dosage of sufentanil given through
the epidural versus intravenously so we are unable to tell
if the dosage was equal in both groups. If the intraven-
ous sufentanil group received a higher ivMEQ, this
would confirm previous observations that synthetic
lipophilic opioids can negatively impact cancer-related
outcomes. Given that our epidural cohort did not re-
ceive the opioid-sparing effect that is normally seen with
hydrophilic opioid-based regional analgesia, our study
adds support for decreased use of systemic opioids for
patients recovering from cancer surgeries. Due to the in-
hibitory effects of opioids on not only NK cell function
but also immunological pathways involving monocytes,
secretion of immunoglobulins, cytokines and cell prolif-
eration [8, 23], the increased systemic absorption caused
by lipophilic, potent analgesics such as sufentanil may be
detrimental for our cystectomy patients.
The issue of opioid use in the perioperative period has
been increasingly recognized in the literature. The role of
the mμ opioid receptor (MOR), which has been shown
expressed in cancer cells such lung adenocarcinoma and
breast cancer, has been postulated as a mechanism of can-
cer progression due its interactions with angiogenesis,
epithelial-mesenchymal transition, and the mammalian
target of rapamycin signaling pathways [24–26]. These
findings have been substantiated by retrospective data
suggesting worse outcomes in patients with cancer who
are exposed to systemic opioids and high levels of MOR
expression [24, 27, 28]. Although our study adds more evi-
dence on the detrimental effect of synthetic opioids, our
findings require further translational studies which may
Table 4 Cox proportional hazards regression for cancer-specific survival (n = 430)
Covariate Level Univariable Hazard
Ratio (95% CI)
P-value aMultivariable Hazard
Ratio (95% CI)
P-value
Age 0.99 (0.97–1.01) 0.448
Gender Male 1.14 (0.70–1.85) 0.600
Female Ref
ASA ≥ 3 1.24 (0.85–1.82) 0.256
≤ 2 Ref
Anesthesia GA + Epidural 1.33 (0.91–1.95) 0.146 1.53 (1.04–2.25) 0.030
GA Ref
pN stage N+ 3.70 (2.52–5.43) < 0.001 2.48 (1.64–3.74) < 0.001
N0/Nx Ref
pT stage ≥ T3 4.98 (3.31–7.51) < 0.001 3.63 (2.32–5.68) < 0.001
≤ T2 Ref
Margin (radial/
ureteral/urethral)
Positive 2.38 (1.56–3.62) < 0.001 2.00 (1.29–3.09) 0.012
Negative Ref
Neoadjuvant
chemotherapy
Yes 1.34 (0.90–1.99) 0.151
No Ref
Adjuvant chemotherapy Yes 2.03 (1.35–3.04) 0.0006
No Ref
aResults are from a backwards selection process (significance level at 0.05)
Bold value indicates statistical significance
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help further characterize the pathophysiological basis of
MOR inhibition and identify potential targets for future
therapeutic strategies.
Several important limitations are inherent in this study
including a limited sample size and the retrospective,
observational design. Although we used propensity score
matching to reduce selection bias, the effects of unmeas-
ured confounding variables cannot be excluded. Our
results relate to only sufentanil epidural anesthesia and
do not translate to other neuraxial anesthetic techniques.
Additionally, any association between anesthetic tech-
niques and oncologic outcomes among patients with
bladder cancer will need to be better characterized from
a pathophysiological standpoint for our results to have
not only epidemiological but therapeutic implications.
Conclusions
Worse oncologic outcomes may be associated with
sufentanil based epidural anesthesia during radical cyst-
ectomy. This may have been due to the larger amount of
opioids used with epidural sufentanil. Although limited
by its retrospective design, our study suggests that fur-
ther investigation in the clinical setting evaluating the ef-
fects of opioid-based epidural analgesia and bladder
cancer progression is warranted.
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